The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Manipulation of the Microbiota for Treatment of IBS and IBD—Challenges and Controversies
Open accessAbstract
There is compelling rationale for manipulating the microbiota to treat inflammatory bowel diseases (IBDs). Although studies of animal models of intestinal inflammation produced promising results, trials in humans have been disappointing. In contrast to IBD, the role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been considered, but early stage results have been encouraging. As pharmaceutical companies develop fewer truly novel agents for treatment of these disorders, consumers seek safer, long-term strategies to deal with chronic symptoms. We assess the rationale for modulating the microbiota for treatment of IBD and IBS, and discuss whether current concepts are simplistic and overstated or simply under-researched. Are claims exaggerated and expectations unrealistic? Difficulties with microbiota terminology and technologies, as well as differences among patients and the heterogeneity of these diseases, pose additional challenges in developing microbiota-based therapies for IBD and IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In some instances, changed microbiota may be an appropriate response to a change in the host, or may represent an epiphenomenon without pathophysiological implications [22] .”
From Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis (2014) · cites this paper as [22]
In the citing paper
“Despite the therapeutic potential of FMT for the treatment of PD, several limitations still exist and need to be addressed. Standard clinical protocols, delivery methods, periodicity, donor’s selection criteria, patient’s inclusion criteria, long-term benefits and potential risks remain an issue [463,467,481,482,483,484,485].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [483]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Consumption of fermented milk product with probiotic modulates brain activity
Tillisch, K., Labus, J., Kilpatrick, L., Jiang, Z., Stains, J., Ebrat, B., Guyonnet, D., Legrain–Raspaud, S., Trotin, B., Naliboff, B., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.043 · Cited by 1,192
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
O'Mahony, S. M., Marchesi, J. R., Scully, P., Codling, C., Ceolho, A.-M., Quigley, E. M. M., Cryan, J. F., & Dinan, T. G. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.026 · Cited by 1,069
Self-citationRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
The microbiome-gut-brain axis: from bowel to behavior
Cryan, J. F., & O’Mahony, S. M. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01664.x · Cited by 990
Bacteria, Colonic Fermentation, and Gastrointestinal Health
Macfarlane, G. T., & Macfarlane, S. (2012) · Journal of AOAC INTERNATIONAL · doi:10.5740/jaoacint.sge_macfarlane · Cited by 970
Cadwell, K., Patel, K., Maloney, N. S., Liu, T., Ng, A., Storer, C. E., Head, R. D., Xavier, R. J., Stappenbeck, T. S., & Virgin, H. W. (2010) · Cell · doi:10.1016/j.cell.2010.05.009 · Cited by 927
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Jeffery, I. B., O'Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., & Simrén, M. (2012) · Gut · doi:10.1136/gutjnl-2011-301501 · Cited by 835
Self-citationEradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–172 of 172
Trasplante de microbiota fecal
de Paredes, A. G. G., de Santiago, E. R., Aguilera, L., Ferre‐Aracil, C., & López–Sanromán, A. (2014) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2014.07.010 · Cited by 17
Effects of CPEB1 in the anterior cingulate cortex on visceral pain in mice
Wang, X., Yue, J., Hu, L., Tian, Z., Yang, L.-K., Lu, L., Zhao, M., & Liu, S. (2019) · Brain Research · doi:10.1016/j.brainres.2019.02.001 · Cited by 15
Progress in Our Understanding of the Gut Microbiome: Implications for the Clinician
Iqbal, S., & Quigley, E. M. M. (2016) · Current Gastroenterology Reports · doi:10.1007/s11894-016-0524-y · Cited by 19
Self-citationCause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis
Denton, C. P., & Murray, C. D. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1872-4 · Cited by 15
Matsui, K., Tani, R., Yamasaki, S., Ito, N., Hamada, A., Shintani, T., Otomo, T., Tokumaru, K., Yanamoto, S., & Okamoto, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116077 · Cited by 16
Tang, H., Chen, X., Huang, S., Gang, Y., Wang, X., & Shen, G.-M. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0155 · Cited by 14
Bai, T., Zeng, H., Long, Y., Li, X., Sun, X., Lan, Y., Gao, L., Zhang, L., Feng, Z., & Hou, X. (2020) · Trials · doi:10.1186/s13063-020-04490-0 · Cited by 14
Hsu, C.-Y., Ahmad, I., Maya, R. W., Abass, M. A., Gupta, J., Singh, A., Joshi, K. K., Premkumar, J., Sahoo, S., & Khosravi, M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06527-x · Cited by 15
Dong, Y., Baumeister, D., Berens, S., Eich, W., & Tesarz, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00714 · Cited by 13
Neuropathy in COVID-19 associated with dysbiosis-related inflammation
Aktaş, B., & Aslım, B. (2021) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-2105-53 · Cited by 12
“Interactions between the gut microbiota and the brain have been explored, and the results indicate that intermediaries resulting from the interaction between the gut immune system and the microbiota may impact the brain functions (Mayer et al., 2014; Shanahan and Quigley, 2014).”
Backgroundİlhan, N. (2018) · International journal of medical biochemistry/International journal of medical biochemistry : · doi:10.14744/ijmb.2018.92400 · Cited by 13
New treatment options for irritable bowel syndrome with predominant diarrhea
Weber, H. C. (2016) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000302 · Cited by 9
Li, M., Li, Z., Shu, W., Liu, Y., Wang, Y., & Tang, L. (2016) · Future Microbiology · doi:10.2217/fmb-2015-0002 · Cited by 11
Zhang, J., Ren, F., Liu, P., Zhang, H.-K., Zhu, H., Feng, Z., Zhang, X., Wang, B., Liu, X., Zhang, X., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i46.8217 · Cited by 10
Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00009-0 · Cited by 8
Zhang, Y., Zhang, J., Xu, T., Zhang, C., Yu, W., Wei, T., Zhang, B., Chen, Q., Qiu, J., Li, H.-J., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/6417658 · Cited by 9
“Moreover, our fi ndings also highlighted the need to investigate gut microbiota interventions, such as pro-biotics and fecal transplants, which have been documented to have superior e ffi cacy, although they are considered optional therapeutic approaches [46, 47].”
The Role of the Human Gut Microbiome in Inflammatory Bowel Disease and Radiation Enteropathy
Fernandes, D., & Andreyev, J. N. (2022) · Microorganisms · doi:10.3390/microorganisms10081613 · Cited by 9
“In short, it cannot be definitively concluded that they improve IBD symptoms [143], and so further research is required to confirm their potential benefits.”
BackgroundElectrolyte Secretion and Absorption in the Small Intestine and Colon
Barrett, K. E., & Keely, S. J. (2015) · Yamada's Textbook of Gastroenterology · doi:10.1002/9781118512074.ch24 · Cited by 9
Gou, X., Zhang, L., Zhao, S., Ma, W., & Yang, Z. (2021) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2103.03017 · Cited by 10
“The clinical efficacy of probiotics in some diseases, such as antibiotic-associated diarrhea [2], Clostridium difficileassociated diarrhea [3], and irritable bowel syndrome and inflammatory bowel disease [4] has been determined by manipulating the microbiota with probiotics.”
BackgroundProbiotics, prebiotics, synbiotics in prevention and treatment of inflammatory bowel diseases
Ivanovska, T. P., Pavlova, M. J., Mladenovska, K., & Petrushevska‐Tozi, L. (2014) · Macedonian Pharmaceutical Bulletin · doi:10.33320/maced.pharm.bull.2014.60.02.001 · Cited by 8
Le transfert de flore digestive : une revue de la littérature
Barbut, F., Collignon, A., Butel, M. J., & Bourlioux, P. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2014.05.004 · Cited by 10
Ye, Z., Kini, A., Tan, Q., Woltemate, S., Vital, M., Nikolovska, K., & Seidler, U. E. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109847 · Cited by 9
Gut Microbiota Dysbiosis and COVID-19: Possible Links
Aktaş, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00072-3 · Cited by 7
Mechanism-Oriented Therapy of Irritable Bowel Syndrome
Malagelada, J. R., & Malagelada, C. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0336-3 · Cited by 7
Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD)
Abraham, B. P., & Quigley, E. M. M. (2014) · Springer eBooks · doi:10.1007/978-3-319-26890-3_8 · Cited by 7
Self-citationThe human gut microbiome, diet, and health: “Post hoc non ergo propter hoc”
Roeselers, G., Bouwman, J., & Levin, E. (2016) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2016.08.010 · Cited by 7
Lallès, J. P., Michel, C., Theodorou, V., & Segain, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801383-0.00017-7 · Cited by 6
Mitigation of Foodborne Illnesses by Probiotics
Ryan, V., & Bhunia, A. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-56836-2_21 · Cited by 6
The Human Microbiome in Health and Disease
Hill, C. J., Ross, R. P., Stanton, C., & O’Toole, P. W. (2016) · Wiley eBooks · doi:10.1002/9783527682386.ch4 · Cited by 6
A Probiotic for Ulcerative Colitis: The Culture Wars Continue
Abraham, B. P., & Quigley, E. M. M. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5097-1 · Cited by 5
Self-citationProbiotics and Their Health Benefits
Fleet, M., & Rahman, P. K. S. M. (2017) · doi:10.1002/9781119048961.ch11 · Cited by 5
Hygiene hypothesis: association between hygiene and asthma among preschool children in Lebanon
Hallit, S. R., Sacre, H., Kheir, N., Hobeika, E., Hallit, R. R., Waked, M., & Salameh, P. (2021) · Allergologia et Immunopathologia · doi:10.15586/aei.v49i1.41 · Cited by 4
Targeting the gut microenvironment in IBS to improve symptoms
Simrén, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00718-3 · Cited by 4
Probiotics and Health: A Review
Tomar, P., Sharma, S., & Dangi, N. (2023) · Current Probiotics · doi:10.2174/2666649901666230509155058 · Cited by 4
Dosh, L., Rappa, F., Jurjus, A. R., Karam, G., Lezeik, R., Masri, J. E., Bucchieri, F., Leone, A., & Jurjus, R. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010130 · Cited by 4
Shanahan, F. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14230 · Cited by 4
Self-citationPharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut–Brain Interaction
Camilleri, M., Sarnelli, G., Andresen, V., Meerveld, B. G., Howden, C. W., Izzo, A. A., & Jones, K. L. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.02.010 · Cited by 3
A Survey Using the Social Networks Revealed Poor Knowledge on Fecal Microbiota Transplantation
Orduña, P., Lopez, S. Y., Schmulson, M. J., Arredondo‐Hernández, R., de Leon, S. P., & López‐Vidal, Y. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm14146 · Cited by 3
“Further, FMT has several advantages in comparison with the treatment with probiotics by the possibility of longer colonization in the adult intestine.(10)”
Insights into Autophagy in Microbiome Therapeutic Approaches for Drug-Resistant Tuberculosis
Rahim, M. A., Seo, H., Barman, I., Hossain, M. S., Shuvo, M. S. H., & Song, H.-Y. (2025) · Cells · doi:10.3390/cells14070540 · Cited by 5
“Differences in individuals’ microbiomes, immune system function, and genetic predisposition can lead to inconsistent therapeutic outcomes, thereby complicating the development of universally effective treatments [178].”
Translating Microbiome Science to Society—What’s Next?
Shanahan, F., & Fitzgerald, G. F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802304-4.00022-0 · Cited by 3
Self-citationEditorial: probiotics and IBS – where are we now?
Moran, C. P., & Shanahan, F. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12836 · Cited by 3
“The greatest impediment is the assumption that all probiotics are equal.(1)”
BackgroundSelf-citationGut Dysbiosis in Insomnia and Diurnal Cycle
Kumar, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-6760-2_8 · Cited by 2
Pediatric Fecal Microbiota Transplantation
Mir, S. A. V., Kellermayer, R., & Gulati, A. (2014) · Current Pediatrics Reports · doi:10.1007/s40124-014-0049-5 · Cited by 2
Diversity: From Diet to Flora to Life
Hanaway, P. J. (2014) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2014.022 · Cited by 2
Clister, D., Chandra, Q. M., Tan, M.-S., Gunawan, M. C., Bibi, A., Ahmed, A., Bastian, M., Meesakul, P., Cao, S., Kim, B., et al. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101596 · Cited by 1
Fulfilling the Promise of Microbiomics to Revolutionize Medicine
Testerman, T. L. (2015) · Journal of Microbiology & Experimentation · doi:10.15406/jmen.2015.02.00050 · Cited by 1
“The disadvantage of these treatments is that there is no evidence that the microbiome is permanently altered by probiotics, meaning that long-term treatment is required [13].”
BackgroundManagement of irritable bowel syndrome in children
Malagelada, J. (2018) · Journal of Pediatrics and Pediatric Medicine · doi:10.29245/2578-2940/2018/3.1127 · Cited by 1
Heesemann, J. (2016) · Springer-Lehrbuch · doi:10.1007/978-3-662-48678-8_3 · Cited by 1
İrritabl Bağırsak Sendromu ve Fonksiyonel Dispepsi Tedavisinde Probiyotikler ve Prebiyotikler
AĞCA, G., YALÇIN, E., & Göktaş, Z. (2019) · Hacettepe Üniversitesi Sağlık Bilimleri Fakültesi Dergisi · doi:10.21020/husbfd.437227 · Cited by 1
Kingsley, M. J., & Moshiree, B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813037-7.00030-3 · Cited by 1
The impact of host-microbe interactions on murine colonic secretomotor function
Lomasney, K. W. (2014) · Cork Open Research Archive (University College Cork, Ireland)
Moré, M. I., & Swidsinski, A. V. (2015) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-015-3691-0
Iraporda, C. (2016) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/51913
Dietary Interventions and Irritable Bowel Syndrome
Thomas, A., & Quigley, E. M. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802304-4.00020-7
Self-citationSynbiotic Adjuvant Therapy in Atopic Dermatitis: Our Experience
Rial, M. J., & Seoane Rodríguez, M. (2016) · Journal of Pharmacy and Nutrition Sciences · doi:10.6000/1927-5951.2016.06.03.2
“The intestinal bacterial flora is involved in many immune functions such: reduce the antigenic load, inhibit colonization by pathogenic microorganisms, reduce intestinal permeability, secrete Th1 cytokines, induce Treg cells, production of secretory IgA or decrease the levels of IgE among others [12-15].”
BackgroundIrritable bowel syndrome: dietetic recommendations and principles of treatment
Makarenko, E. V. (2017) · Vestnik of Vitebsk State Medical University · doi:10.22263/2312-4156.2017.6.23
Novel Strategies for Targeting the Control of Mucosal Inflammation
Ernst, P. B., Drygiannakis, I., & Chu, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-811924-2.00052-3
Irritable bowel syndrome and small intestinal bacterial overgrowth: Assessment with breath test
Costa, L., Gomes, T., Braga, C., Lenz, L., Miszputen, S. J., & Ambrogini, O. (2020) · Archives of Clinical Gastroenterology · doi:10.17352/2455-2283.000077
“Currently, the available techniques for the diagnosis of SIBO include the quantitative culture of jejunal aspirate and breath tests, using lactulose or glucose as the substrate [17,2426].”
BackgroundMethodVoloshyn, O. I., Voloshyna, L. O., Vasiuk, V. L., & Patratiy, M. V. (2020) · Ukrainian Therapeutical Journal · doi:10.30978/utj2020-4-75
Tannock, G. W. (2016) · Wiley eBooks · doi:10.1002/9781118801413.ch9
Zeng, H., Bai, T., Long, Y., Li, X., Sun, X., Lan, Y., Gao, L., Zhang, L., Feng, Z., & Hou, X. (2019) · Research Square · doi:10.21203/rs.2.13843/v2
Zeng, H., Bai, T., Long, Y., Li, X., Sun, X., Lan, Y., Gao, L., Zhang, L., Feng, Z., & Hou, X. (2019) · Research Square · doi:10.21203/rs.2.13843/v1
Heesemann, J. (2020) · Springer eBooks · doi:10.1007/978-3-662-61385-6_3
Analysis of the gut microbiome of Japanese inflammatory bowel disease patientsPreprint
Fukui, Y., Nakajima, H., Aoki, K., Toshihide, O., Tateda, K., & Urita, Y. (2019) · Research Square · doi:10.21203/rs.2.10838/v1
“Alterations in microbiome and their metabolites are known to be involved not only in IBD pathogenesis but also in different phases of disease progression, including development of complications and extraintestinal disorders [41, 42].”
BackgroundXu, H., Chen, Q., Fan, Y., Zhang, B., Yan, C., Zhang, Q., Ke, Y., Chen, Z., Wang, L., Shi, H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1606914/v1
López-López, C. D., & Fonseca‐Camarillo, G. (2023) · Revista mexicana de enfermedades inflamatorias inmunomediadas · doi:10.24875/imids.m23000038
Insights in the Cross-Talk Between Microbiota-Gut-Brain Axis: A Focus on Alzheimer’s Disease
Soni, T., Jawanda, I. K., Kumari, S., & Prabha, V. (2023) · Springer eBooks · doi:10.1007/978-981-99-3126-2_22
Bai, T., Zeng, H., Long, Y., Li, X., Sun, X., Lan, Y., Gao, L., Zhang, L., Feng, Z., & Hou, X. (2020) · Figshare · doi:10.6084/m9.figshare.12592620
Gut microbiota from health to disease: A role for biofilms?
Buret, A. G., & Allain, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40306-4.00011-9
Management of Irritable Bowel Syndrome in the Patient with Ulcerative Colitis
Ginsburg, P. M., & Bayless, T. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1677-1_40
Metadata
- Authors
- Shanahan, F., & Quigley, E. M. M.
- Affiliations
- National University of Ireland (IE)
- Houston Methodist (US)
- Corresponding author
- Shanahan, Fergus
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 146
- Issue
- 6
- Pages
- 1554-1563
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2172135635
- Cited by
- 172
- References
- 67
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 7 · 2023: 7 · 2022: 11 · 2021: 12 · 2020: 12 · 2019: 17 · 2018: 13 · 2017: 20 · 2016: 27 · 2015: 22 · 2014: 17
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, microbiota-based therapy, irritable bowel syndrome, inflammatory bowel disease, microbiota modulation, intestinal inflammation, disease heterogeneity
- MeSH terms
- Animals, Biological Therapy, Feces, Humans, Intestines, Inflammatory Bowel Diseases, Treatment Outcome, Probiotics, Irritable Bowel Syndrome, Host-Pathogen Interactions, Prebiotics, Microbiota, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
